AI-generated research brief — verify at source
Liposuction Markedly Outperforms Conservative Therapy for Pain Relief in Lipoedema
In a multicentre randomised controlled trial, liposuction achieved clinically meaningful leg pain reduction in 68% of patients compared with only 8% of those continuing conservative therapy — a more than 26-fold higher odds of success (OR 26.2, 95% CI 13.1–52.5; p<0.0001). The benefit came with a trade-off: serious adverse events were nearly three times more common in the liposuction group (8% vs 3%).
What Was Studied
The trial investigated whether liposuction is superior to conservative complex decongestive therapy in achieving a clinically meaningful reduction in leg pain — defined as at least a 2-point decrease on a 0–10 numeric rating scale — after 12 months of follow-up. This question is important because conservative therapy, the current standard of care, provides only limited symptom relief for patients with lipoedema, a painful chronic condition of subcutaneous adipose tissue affecting predominantly women.
How It Was Studied
This was a multicentre randomised controlled trial conducted across 11 centres in Germany. Eligible participants were women with stage I, II, or III lipoedema who reported baseline leg pain of at least 4 points on a 0–10 numeric rating scale. All enrolled patients first underwent up to 7 months of conservative therapy before being randomly assigned in a 2:1 ratio to either proceed to liposuction (n=278) or continue conservative therapy (n=132), with stratification by lipoedema stage and study site. Of 1,973 patients screened, 453 were enrolled and 410 were ultimately randomised and included in the intention-to-treat analysis. To reduce assessor bias, leg patches were applied to all participants and patients were instructed not to disclose their treatment allocation to assessors, though full blinding was not feasible given the nature of the surgical intervention.
What Was Observed
- Primary pain endpoint: 190 of 278 patients (68%) in the liposuction group achieved the primary endpoint of at least a 2-point reduction in leg pain at 12 months, compared with only 10 of 132 (8%) in the conservative therapy group. This represents a dramatically higher likelihood of pain relief with surgery — more than 26 times the odds (OR 26.2, 95% CI 13.1–52.5; p<0.0001).
- Adverse events: Nearly half of liposuction patients (47% of 265) experienced at least one adverse event, compared with 21% of 145 patients in the conservative group. Serious adverse events were recorded in 20 liposuction patients (8%) versus 5 conservative therapy patients (3%), indicating a meaningfully higher safety burden with the surgical approach.
- Quality of life: Secondary endpoints assessing quality of life showed greater improvement in the liposuction group than in the conservative therapy group, consistent with the primary pain findings.
Why This Matters
Lipoedema is a painful, chronic disease that predominantly affects women, and conservative complex decongestive therapy — the current standard of care — has long been acknowledged as offering only limited symptom relief. This trial provides direct, randomised evidence that liposuction can deliver substantially greater pain reduction and quality-of-life improvement, offering a basis for reconsidering treatment pathways in clinical guidelines. The scale and design of this study represent a significant step toward establishing an evidence-based surgical option for a condition where robust trial data have historically been absent.
How to Read This Result
This large, high-quality multicentre RCT demonstrates a strong and statistically robust benefit of liposuction over conservative care at 12 months, but the durability of this effect and the full long-term safety profile remain uncertain until the ongoing 36-month follow-up data become available.
Limitations
Ethnicity data were not collected, limiting the generalisability of findings across diverse populations. Full blinding was not achievable — while assessor masking was attempted using leg patches, patients were necessarily aware of their treatment assignment, which may have influenced self-reported outcomes. The 2:1 randomisation ratio and the open-label nature of the intervention introduce the possibility of bias. Critically, the 36-month follow-up is still ongoing, meaning that conclusions about the long-term durability of pain relief and the delayed consequences of surgery cannot yet be drawn.